Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.

Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton WJ, Saw RPM, Thompson JF, Menzies AM, Long GV, Scolyer RA, Palendira U.

Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29.

PMID:
29599411
2.

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Gide TN, Wilmott JS, Scolyer RA, Long GV.

Clin Cancer Res. 2018 Mar 15;24(6):1260-1270. doi: 10.1158/1078-0432.CCR-17-2267. Epub 2017 Nov 10. Review.

PMID:
29127120
3.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.

PMID:
28776578

Supplemental Content

Support Center